Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

SGLT-2

This page shows the latest SGLT-2 news and features for those working in and with pharma, biotech and healthcare.

The year of the blockbuster

The year of the blockbuster

The diseases targeted by the report’s projected market entrants include type 2 diabetes, endometriosis, childhood epilepsy, haemophilia, HIV, migraine, opioid addiction and shingles. ... Steglatro (ertugliflozin) from Pfizer and Merck:Sodium glucose

Latest news

  • Novo’s diabetes pill defeats Merck’s Januvia in trial Novo’s diabetes pill defeats Merck’s Januvia in trial

    PIONEER 4 saw the enrolment of 711 people with type 2 diabetes inadequately controlled on metformin, or without an SGLT-2 inhibitor. ... Patients achieved a 4.7 and 5.0kg loss compared to 3.2 and 3.1kg with Victoza and 0.7 and 1.2kg with placebo.

  • FDA panel backs CV claims for Novo Nordisk's Victoza FDA panel backs CV claims for Novo Nordisk's Victoza

    The positive vote from EMDAC puts us one step closer to expanding our offering to reduce the risk of cardiovascular events in people with type 2 diabetes.". ... Victoza is the second drug to get a recommendation for improving cardiovascular outcomes in

  • AZ gets US approval for diabetes combo Qtern AZ gets US approval for diabetes combo Qtern

    The US FDA has approved AstraZeneca's Qtern, a two-drug therapy for type 2 diabetes, after rejecting the drug in 2015. ... The approval of Qtern is good news for patients who may benefit from improved glycaemic control by adding a DPP-4 inhibitor to a

  • New Jardiance label could boost sales by $1.7bn, says analyst New Jardiance label could boost sales by $1.7bn, says analyst

    New Jardiance label could boost sales by $1.7bn, says analyst. Diabetes treatment can reduce the risk of cardiovascular death in type 2 patients. ... It is the first time that any diabetes treatment has been approved with a cardiovascular claim and -

  • AZ looks beyond diabetes with Forxiga trials AZ looks beyond diabetes with Forxiga trials

    The company is also starting new mechanistic trials designed to understand "the underlying science behind the potential cardiovascular and renal protective signals seen with the SGLT-2 inhibitor class". ... Boehringer and Lilly have already reported a

More from news
Approximately 7 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • Deal Watch November 2015 Deal Watch November 2015

    2, 700. Cardioxyl Pharmaceuticals. Bristol-Myers Squibb. Acquisition - company. Lead asset: p2 CXL-1427, nitroxyl (HNO) donor (prodrug) - iv treatment for acute decompensated heart failure (ADHF). ... 2, 075. Lexicon Pharmaceuticals. Sanofi. Collaboration

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Quick links

Infographics

Multimedia